CAT abandons Trabio after second clinical trial failure
Cambridge Antibody Technology's Trabio (lerdelimumab), a treatment for improving outcomes in glaucoma filtration surgery, has failed to meet the primary endpoint in its second and final pivotal study and the company will now abandon the drug's development for this indication.
The result confirms the findings of the first pivotal clinical study, which was announced in November 2004 At that point, the firm reported it would minimize all further development costs associated with the drug (Marketletter November 15, 2004)
Peter Chambre, chief executive of CAT, emphasized that the company had planned for this outcome and said: "we will focus our resources on product opportunities such as the AstraZeneca alliance, GC-1008 with Genzyme, and CAT-354, our proprietary asthma candidate."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze